JILIN--Pfizer Animal Health, a business unit of Pfizer (NYSE: PFE), and
Jilin Guoyuan Animal Health Co., Ltd., announced today the establishment
of the joint venture Jilin Pfizer Guoyuan Animal Health Co., Ltd.
The joint venture, which has been granted a license by local Chinese
government authorities, formalizes the strategic agreement signed on
September 8 to develop, manufacture, and distribute animal vaccines in
China. Terms of the agreement were not disclosed.
The new company will focus initially on swine vaccine development and
commercialization. In the future, it will consider new opportunities to
offer Chinese livestock producers a comprehensive range of vaccine
products to help protect the health of food production animals.
“As Chinese society is becoming more affluent, demand for meat,
especially pork, is rapidly increasing. A quality, affordable food
supply begins with healthy animals,” said Juan Ramón Alaix, president,
Pfizer Animal Health. “We believe Jilin Pfizer Guoyuan will meet China’s
livestock producers’ needs for quality vaccines to help protect the
health of food production animals.”
He added that Pfizer Animal Health views China as a center for
innovation. “The joint venture with Jilin Guoyuan not only demonstrates
Pfizer Animal Health’s commitment to growth in China but also will help
accelerate the development of China’s animal health industry,” Alaix
said. “In Jilin Guoyuan we found the ideal partner with the company’s
scientific expertise, a strong early to late stage vaccine development
program, and a new manufacturing facility in the Huinan Economic
Development Zone. We are confident that our collaboration with Jilin
Guoyuan will deliver value to China’s livestock producers and the
veterinarians who support them.”
“It is our pleasure to have Pfizer as our partner. We share the same
vision and mission in the field of animal health. We will jointly
achieve success in swine vaccines and other animal health products in
China,” said Dr. Wu Hua, former General Manager of Jilin Guoyuan Animal
Health Co., Ltd. “Building up the strategic partnership with Pfizer is
just the first step, and Jilin Pfizer Guoyuan will further offer our
resources and expand our business countrywide and overseas. In this way,
both parties will make a contribution to the development of China’s
animal health industry in the near future.”
China’s animal vaccines market is valued at $800 million. Vaccines for
swine have high growth potential as China is the world’s leading pork
producing nation, with an annual population of more than 600 million
pigs. The joint venture provides a strategic platform for growth in
China, a $3.4 billion1 animal health market and the second largest in
the world with an expected compound annual growth rate of approximately
ten percent.
About Jilin Guoyuan Animal Health Company
Jilin Guoyuan Animal Health Company was established in 2009 and has been
mainly engaged in R&D, manufacturing and sales of animal health
biological products. It has set up its manufacturing base in Huinan
Economic Development Zone in Jilin, which includes a GMP certified
production building, animal housing for quality testing, an
administrative office building and other auxiliary buildings.
About Pfizer Animal Health
Pfizer Animal Health (PAH) is one of the world’s largest animal health
production companies, leading the global animal health production
industry. PAH provides a comprehensive range of medicines, vaccines and
animal health services and works to assure that companion animals live
longer, healthier lives and to assure a quality, sustainable global food
supply from healthy livestock.
PAH-China has registered and launched a series of products for swine,
dairy cattle, poultry and companion animals, including vaccines,
antibiotics, parasiticides and disinfectants. Improvac, a novel vaccine
for swine approved in September, 2010, further expanded PAH’s products
in China.
Relying on strength In R&D and product line, PAH works to provide animal
health solutions of high quality and efficiency, and comprehensive
services of high quality, with the aim to promote the development of
China husbandry.
For more information about Pfizer Animal Health, please visit https://animalhealth.pfizer.com.
PAH Contact:
Ping Yu
Tel: 020-8384806-883
Email: ping.yu@pfizer.com